Repurposed nystatin to inhibit SARS-CoV-2 and mutants in the GI tract
E. Virag, D. Seffer, A. Penzes-Huvos, K. Varajti, G. Hegedus, I. Jankovics, J. P. Pallos
This study investigates nystatin as an antiviral agent against SARS-CoV-2 and its mutants in the gastrointestinal tract, showing it inhibits viral replication at 62.5 g/ml.
bioRxiv · Oct 19, 2021Pharmacology & Toxicology